<DOC>
	<DOCNO>NCT01879241</DOCNO>
	<brief_summary>The primary objective trial investigate survival time ( time randomization death end trial ) compare control group experimental group . This prospective , multicenter , randomize , stratify , parallel-group , double-blind trial compare placebo 1 mg/d rasagiline add-on therapy 100 mg riluzole amyotrophic lateral sclerosis ( ALS ) 250 enrolled patient . For entry , El Escorial Criteria diagnosis ALS use . The patient stable riluzole least 4 week prior randomization .</brief_summary>
	<brief_title>Study Rasagiline Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Possible , probable ( clinically laboratory ) definite ALS accord revise version El Escorial World Federation Neurology criterion Disease duration 6 month le 3 year ( inclusive ) . Disease onset defined date first muscle weakness , exclude fasciculation cramp Vital capacity 50 % normal ( slow vital capacity ; best three measurement ) Age : â‰¥ 18 year Continuously treat 100 mg riluzole least four week Capable thoroughly understand information give give full inform consent accord GCP Women childbearing age must nonlactating surgically sterile use highly effective method birth control negative pregnancy test . Acceptable method birth control low failure rate i.e . le 1 % per year ) use consistently correct implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , doublebarrier method ( condom diaphragm spermicidal agent IUD ) , sexual abstinence vasectomize partner Previous participation another clinical study within precede 12 week Tracheostomy assist ventilation type precede three month Gastrostomy Any medical condition know association motor neuron dysfunction might confound obscure diagnosis ALS Presence concomitant lifethreatening disease impairment likely interfere functional assessment Patients sympathomimetic agent . This include pseudoephedrine , phenylephrine , phenylpropanolamine , ephedrine . Patients analgesic serotoninergic property meperidine , tramadol , methadone propoxyphene . Patients serotonin reuptake inhibitor ( SSRIs ) . This include fluoxetine fluvoxamine . Patients dextromethorphan , St. John 's wort , cyclobenzaprine MAO inhibitor ( selective nonselective ) Patients take Antidepressants Confirmed hepatic insufficiency abnormal liver function ( ASAT and/or ALAT great 3 time upper limit normal range ) Renal insufficiency ( serum creatinine 2.26 mg/dL ) Evidence major psychiatric disorder clinically evident dementia preclude evaluation symptom Known hypersensitivity component study drug Liable cooperative comply trial requirement ( assessed investigator ) , unable reach case emergency Female childbearing potential , adequate contraceptive measure use Pregnancy breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>survival time</keyword>
	<keyword>ALS function Rating Scale</keyword>
	<keyword>quality life</keyword>
	<keyword>survival</keyword>
</DOC>